SciSparc's NeuroThera launches Tourette syndrome trial site at Yale

SciSparc Ltd. announced on August 5, 2026 that its subsidiary NeuroThera Labs Inc. initiated a Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, in New Haven, Connecticut.¹ The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera's proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome in adults.¹

SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in a single dosage form designed to reduce tics and associated comorbid symptoms in adults with Tourette Syndrome while aiming to minimize side effects.¹ With the Yale site now active, the Phase IIb trial runs at three locations total: the Yale site, Hannover Medical School in Hanover, Germany, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.¹

The company pointed to earlier data as the basis for the current study, noting that the Phase IIb trial builds on positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participant sample, as measured by the Yale Global Tic Severity Scale Total Tic Score.¹ The Phase IIb study itself is described as a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110.¹

Trial design specifics include that patients aged 18 to 65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline.¹ Safety will be assessed through monitoring of adverse events.¹

SciSparc also disclosed in the filing that forward-looking statements in the release are subject to risks discussed under "Risk Factors" in its Annual Report on Form 20-F filed with the SEC on April 29, 2026, and in subsequent filings.¹